BRIDGEN TO LEAVE ABCWASHINGTON -- Dr. Pamela Bridgen, executive director of theAssociation of Biotechnology Companies, is leaving her postafter two years, the trade group announced Monday.
Bridgen will remain through the summer to allow the ABC tofind a replacement. A search committee, headed by ABCPresident Forrest Anthony and consisting of past ABCpresidents, has been formed.
"ABC has made great headway in its size and diversity ofmembership. It has earned respect as a leading industry voiceat the White House, federal agencies, Capitol Hill, scientificadvisory groups, with the press and industry representatives,"Bridgen said. "Now that I have accomplished the goalsestablished for ABC, I believe it is time for me to tackle newchallenges within the biotechnology industry. I have everyconviction ABC will continue to prosper as a powerful voicefor the industry."
Bridgen told BioWorld that she has not yet lined up a newposition. -- Steve Usdin
FDA POSTPONES PROLEUKIN REVIEW
A Food and Drug Administration advisory committee haspostponed a meeting tentatively scheduled for July 22-23 atwhich it was to have reviewed Cetus Corp.'s Proleukininterleukin-2 to treat kidney cancer. No new date has been set.The postponement was purely a scheduling problem for theFDA, according to a report by Ira Loss of County NatWest'sWashington Analysis Corp. Cetus stock (NASDAQ:CTUS) closedup $1 Monday at $16.50.
TEVA TO OFFER 4.5 MILLION ADRs
Teva Pharmaceutical Industries Ltd. of Jerusalem will offer4.5 million American depositary shares in a public offering,rather than 5 million ADRs as originally announced in mid-May.Following the offering, Teva will have 24.3 million ADRsoutstanding. Underwriters Lehman Brothers and Merrill Lynch &Co. have an option to purchase an additional 450,000 ADRs tocover overallotments.
(c) 1997 American Health Consultants. All rights reserved.